Hsa‐miR‐25‐3p promotes tumor cell proliferation by targeting tumor suppressor BTG2; this miRNA is a new diagnostic and therapeutic target in triple‐negative BC28; however, its potential to be a reliable biomarker in BC is still unclear. This evidence concerns the gene BTG2 and neoplasm.